InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
InflaRx N.V. (IFRX) has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference, scheduled for February 5-6, 2025, in New York. The company specializes in developing anti-inflammatory therapeutics targeting the complement system.
InflaRx's primary focus is on their proprietary anti-C5a and anti-C5aR technologies, which are used to develop inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenous first-in-class anti-C5a monoclonal antibody that has shown promising clinical activity across multiple indications. The company is also developing INF904, an oral small molecule C5a receptor inhibitor.
InflaRx N.V. (IFRX) ha annunciato la sua partecipazione alla prossima Guggenheim SMID Cap Biotech Conference, programmata per il 5-6 febbraio 2025 a New York. L'azienda si specializza nello sviluppo di terapeutiche anti-infiammatorie mirate al sistema del complemento.
Il focus principale di InflaRx è sulle proprie tecnologie anti-C5a e anti-C5aR, utilizzate per sviluppare inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR. Il loro principale candidato prodotto, vilobelimab, è un anticorpo monoclonale anti-C5a di prima classe somministrato per via endovenosa, che ha mostrato un'attività clinica promettente in diverse indicazioni. L'azienda sta anche sviluppando INF904, un inibitore del recettore C5a in forma di piccole molecole da assumere per via orale.
InflaRx N.V. (IFRX) ha anunciado su participación en la próxima Guggenheim SMID Cap Biotech Conference, programada para el 5-6 de febrero de 2025 en Nueva York. La compañía se especializa en el desarrollo de terapias antiinflamatorias dirigidas al sistema del complemento.
El enfoque principal de InflaRx es en sus tecnologías propietarias anti-C5a y anti-C5aR, que se utilizan para desarrollar inhibidores del factor de activación del complemento C5a y su receptor C5aR. Su principal candidato a producto, vilobelimab, es un anticuerpo monoclonal anti-C5a de clase internacional que ha mostrado una actividad clínica prometedora en múltiples indicaciones. La compañía también está desarrollando INF904, un inhibidor del receptor C5a en forma de pequeñas moléculas orales.
InflaRx N.V. (IFRX)는 2025년 2월 5일부터 6일까지 뉴욕에서 열리는 Guggenheim SMID Cap Biotech Conference에 참여한다고 발표했습니다. 이 회사는 보 complement 시스템을 목표로 하는 항염증 치료제를 개발하는 데 특화되어 있습니다.
InflaRx의 주요 초점은 보 complement 활성화 인자인 C5a 및 그 수용체 C5aR에 대한 억제제를 개발하는 데 사용되는 독점적인 항-C5a 및 항-C5aR 기술입니다. 그들의 주요 제품 후보인 vilobelimab는 여러 적응증에서 유망한 임상 활동을 나타내는 첫 번째 클래스의 정맥 주사 항-C5a 단클론 항체입니다. 이 회사는 또한 경구용 소분자 C5a 수용체 억제제인 INF904를 개발하고 있습니다.
InflaRx N.V. (IFRX) a annoncé sa participation à la prochaine Guggenheim SMID Cap Biotech Conference, prévue pour les 5 et 6 février 2025 à New York. L'entreprise est spécialisée dans le développement de thérapies anti-inflammatoires ciblant le système du complément.
Le principal axe de travail d'InflaRx concerne ses technologies propriétaires anti-C5a et anti-C5aR, qui sont utilisées pour développer des inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR. Leur principal candidat produit, vilobelimab, est un anticorps monoclonal anti-C5a de première classe administré par voie intraveineuse, qui a montré une activité clinique prometteuse dans plusieurs indications. L'entreprise développe également INF904, un inhibiteur du récepteur C5a sous forme de petite molécule orale.
InflaRx N.V. (IFRX) hat seine Teilnahme an der bevorstehenden Guggenheim SMID Cap Biotech Conference angekündigt, die für den 5.-6. Februar 2025 in New York geplant ist. Das Unternehmen hat sich auf die Entwicklung von entzündungshemmenden Therapeutika fokussiert, die auf das Komplementsystem abzielen.
Der Hauptaugenmerk von InflaRx liegt auf den proprietären Technologien anti-C5a und anti-C5aR, die zur Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors C5aR eingesetzt werden. Ihr führender Produktkandidat, vilobelimab, ist ein intravenös verabreichter Antikörper der ersten Klasse gegen C5a, der vielversprechende klinische Aktivitäten in verschiedenen Indikationen gezeigt hat. Das Unternehmen entwickelt auch INF904, einen oralen kleinen Molekülinhibitor des C5a-Rezeptors.
- None.
- None.
JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY.
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When and where is InflaRx (IFRX) participating in the Guggenheim SMID Cap Biotech Conference?
What are the main product candidates in InflaRx's (IFRX) pipeline?
What is the therapeutic focus of InflaRx's (IFRX) drug development program?
What type of technology does InflaRx (IFRX) use in its drug development?
